The CDK1 inhibitor, Ro-3306, is a potential antiviral candidate against influenza virus infection.

Many viruses use the host cell division cycle to facilitate replication. Cyclin-dependent kinases (CDKs) are a group of serine/threonine kinases that play a central role in regulating cell cycle progression. However, the prospect of using CDKs for anti-influenza virus treatment remains to be elucidated. We conducted this study to investigate the potential of the CDK1 inhibitor Ro-3306 in preventing influenza virus infection and to elucidate the underlying mechanism. We showed that Ro-3306, a CDK1 inhibitor, exerts anti-influenza activity both in vitro and in vivo. Proof-of-concept studies revealed that knockdown of host CDK1 might affect the splicing of M2 viral mRNA, leading to the restriction of viral replication. Moreover, Ro-3306 directly bound to viral PB2 protein and inhibited viral RNA replication. Transcriptome analysis further revealed that Ro-3306 treatment inhibited the expression of MAPK-regulated genes, which might also contribute to the antiviral activity of Ro-3306. This study highlighted the multifunctional role of Ro-3306 as a novel anti-influenza virus agent. Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Citation

Lei Zhao, Yunzheng Yan, Qingsong Dai, Zihao Wang, Jiye Yin, Yijie Xu, Zhuang Wang, Xiaojia Guo, Wei Li, Ruiyuan Cao, Wu Zhong. The CDK1 inhibitor, Ro-3306, is a potential antiviral candidate against influenza virus infection. Antiviral research. 2022 May;201:105296

Mesh Tags

Substances

PMID: 35367281

search → result